Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Depression is a risk factor for the development of Alzheimer’s disease (AD), and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD. A long-term treatment with antidepressants reduces the risk to develop AD and different second-generation antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are currently studied for their neuroprotective properties in AD. In the present work, the SSRI fluoxetine and the new multimodal antidepressant vortioxetine were tested for their ability to prevent memory deficits and depressive-like phenotype induced by intracerebroventricular injection of amyloid-β (1-42) (Aβ1-42) oligomers in 2-month-old C57BL/6 mice. Starting from 7 days before Aβ injection, fluoxetine (10 mg/Kg) and vortioxetine (5 and 10 mg/Kg) were intraperitoneally injected daily, for 24 days. Chronic treatment with fluoxetine and vortioxetine (both at the dose of 10 mg/Kg) was able to rescue the loss of memory assessed 14 days after Aβ injection by the passive avoidance task and the object recognition test. Both antidepressants reversed the increase in immobility time detected 19 days after Aβ injection by forced swim test. Vortioxetine exerted significant antidepressant effects also at the dose of 5 mg/Kg. A significant deficit of Transforming Growth Factor-β1 (TGF-β1), paralleling memory deficits and depressive-like phenotype, was found in the hippocampus of Aβ-injected mice in combination with a significant reduction of the synaptic proteins synaptophysin and PSD-95. Fluoxetine and vortioxetine completely rescued hippocampal TGF-β1 levels in Aβ-injected mice as well as synaptophysin and PSD-95 levels. This is the first evidence that a chronic treatment with fluoxetine or vortioxetine can prevent both cognitive deficits and depressive-like phenotype in a non-transgenic animal model of AD with a key contribute of TGF-β1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“Synthetic human Aβ1-42 oligomers were prepared according to the original protocol of Klein’s group (Gong et al., 2003).”
MethodCastagné, V., Moser, P., Roux, S., & Porsolt, R. D. (2011) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0810as55 · Cited by 702
Barker, G. R. I., Bird, F., Alexander, V., & Warburton, E. C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5289-06.2007 · Cited by 691
Object recognition memory and the rodent hippocampus
Broadbent, N. J., Gaskin, S., Squire, L. R., & Clark, R. E. (2010) · Learning & Memory · doi:10.1101/lm.1650110 · Cited by 568
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
β-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421 · cited 1×
“Synthetic human Aβ1-42 oligomers were prepared according to the original protocol of Klein’s group as modified and characterized in Giuffrida et al. (2009).”
MethodSelf-citationNeuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Self-citationDeficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology
Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J. V., Lin, A. H., Crews, L., Tremblay, P., Mathews, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27341 · Cited by 355
Pro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy
Sutcigil, L., Oktenli, C., Musabak, U., Bozkurt, A., Cansever, A., Uzun, O., Sanisoglu, S. Y., Yesilova, Z., Ozmenler, N., Ozsahin, A., et al. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/76396 · Cited by 315
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271 · cited 1×
“…a novel, multimodal, mechanism of action, directly acting on several serotonin (5-hydroxytryptamine, 5-HT) receptors (as an agonist on 5-HT1A receptor, a partial agonist on 5-HT1B, and an antagonist on 5-HT1D, 5-HT3, and 5-HT7) besides inhibiting the serotonin transporter (SERT; MØrk et al., 2012).”
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185
Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172 · cited 6×
“This approach was also settled moving from the evidence that secondgeneration antidepressants, such as fluoxetine, exert relevant neuroprotective effects in vitro in experimental models of Aβ-induced neurodegeneration (Caraci et al., 2016; Caraci et al., 2018).”
InfluentialSelf-citationPereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171
The role of IL-12 and TGF-β1 in the pathophysiology of major depressive disorder
Lee, K.-M., & Kim, Y.-K. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.03.015 · Cited by 150 · cited 1×
“Among SSRIs, fluoxetine increases circulating TGF-β1 levels in depressed patients (Lee and Kim, 2006; Sutcigil et al., 2007) and prevents Aβ-induced toxicity in neuronal cultures by increasing the release of TGF-β1 (Caraci et al., 2016).”
BackgroundRole of neuro-immunological factors in the pathophysiology of mood disorders
Bhattacharya, A., Derecki, N. C., Lovenberg, T. W., & Drevets, W. C. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4214-0 · Cited by 149
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113
Caruso, G., Caraci, F., & Jolivet, R. B. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.004 · Cited by 110
Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
Li, Y., Abdourahman, A., Tamm, J. A., Pehrson, A. L., Sánchez, C., & Gulinello, M. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.013 · Cited by 79
TGF-β1 protects against Aβ-neurotoxicity via the phosphatidylinositol-3-kinase pathway
Caraci, F., Battaglia, G., Busceti, C., Biagioni, F., Mastroiacovo, F., Bosco, P., Drago, F., Nicoletti, F., Sortino, M. A., & Copani, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.007 · Cited by 79
Self-citationWang, J., Zhang, Y., Xu, H., Zhu, S., Wang, H., He, J., Zhang, H., Guo, H., Kong, J., Huang, Q., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140812114715 · Cited by 56
Cited by
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“A selective impairment of TGF-β1 pathway is present in early AD, both in the AD brain (121, 122) and in AD animal models (71, 123, 124).”
BackgroundSelf-citationDepression, dementia and immune dysregulation
Hayley, S., Hakim, A. M., & Albert, P. R. (2021) · Brain · doi:10.1093/brain/awaa405 · Cited by 186
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
Hall-Roberts, H., Agarwal, D., Obst, J., Smith, T. B., Monzón-Sandoval, J., Di Daniel, E., Webber, C., James, W. S., Mead, E., Davis, J. B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00709-z · Cited by 62
Metadata
- Authors
- Torrisi, S. A., Geraci, F., Tropea, M. R., Grasso, M., Caruso, G., Fidilio, A., Musso, N., Sanfilippo, G., Tascedda, F., Palmeri, A., Salomone, S., Drago, F., Puzzo, D., Leggio, G. M., & Caraci, F.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-21
- Volume
- 10
- Pages
- 693-693
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2949940216
- Cited by
- 86
- References
- 22
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.